Evaxion Biotech (EVAX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Evaxion Biotech has unveiled promising preclinical results for its cytomegalovirus vaccine program, EVX-V1, utilizing its AI-Immunology platform to trigger targeted immune responses. The innovative approach, which combines AI-identified antigens with a proprietary prefusion glycoprotein B antigen, marks a significant step towards developing an effective CMV vaccine. This development could potentially tap into the growing CMV treatment market, valued at $474.6 million in 2023, and poised for further growth.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
